LONDON (Alliance News) - Amryt Pharma PLC said on Thursday it expects its performance for 2018 to be in line with current market expectations, following strong trading in the first half.
The orphan diseases-focused pharmaceutical company said that for the first six months of 2018 it made progress on all three of its growth pillars.
These are continued revenue growth and expansion of its lead asset Lojuxta, developments of its late stage pipeline, and product acquisition to leverage its infrastructure in rare diseases.
Revenue for the six months to the end of June was EUR7.0 million, up 14% from EUR6.2 million the year before.
Full-year growth expectations are underpinned by a recent reimbursement decision by NHS England for Lojuxta in patients with homozygous familial hypercholesterolaemia and the success of Amryt's strategy to appoint local distribution partners for new territories.
In addition, the phase three clinical trial with AP101 for epidermolysis bullosa has seen progress, with a pre-planned interim efficacy analysis which is expected to be completed in the fourth quarter of 2018, and top-line data expected in the second quarter of 2019.
"We are pleased with the progress that we have made in the first half of 2018 across all aspects of our business and growth strategy. Our focus on adoption of and access to Lojuxta in new and existing territories is already delivering significant returns and we are confident that this positive momentum will continue in 2018 and beyond," said Chief Executive Officer Joe Wiley.
Shares In Amryt Pharma were up 1.9% at 17.85 pence on Thursday.
